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OBJECTIVES This study was performed to investigate the causes of diffuse and aggressive intra-stent
restenosis.
BACKGROUND Although restenosis is usually considered to be a dichotomous variable, there is clinical
relevance to the severity of restenosis. It is not known which variables are predictive of diffuse
or aggressive intra-stent restenosis.
METHODS A consecutive series of 456 coronary lesions with in-stent restenosis was evaluated for the type
of restenosis using quantitative coronary angiography. Restenosis was defined as $50%
diameter stenosis at follow-up angiography, diffuse restenosis as a follow-up lesion length
$10 mm and aggressive restenosis as either an increase in lesion length from the original
lesion or a restenotic narrowing tighter than the original. Clinical, anatomic and procedural
characteristics were evaluated for lesions associated with these types of restenosis.
RESULTS Diffuse restenosis was associated with a smaller reference artery diameter, longer lesion
length, female gender, longer stent length and the use of coil stents. Aggressive restenosis was
more common in women, with the use of Wallstents and with long stent to lesion length
ratios. Aggressive restenosis occurred earlier and was more closely associated with symptoms
and myocardial infarctions than nonaggressive restenotic lesions.
CONCLUSIONS Markers for diffuse restenosis were also important markers for the presence of any restenosis.
A long stent to lesion length ratio is an important marker for aggressive restenosis. When
severe forms of in-stent restenosis occur, they tend to present earlier and with more
symptoms, including myocardial infarction. More careful consideration of the type of in-stent
restenosis may aid in identifying when alternative strategies may be useful. (J Am Coll
Cardiol 2001;37:1019–25) © 2001 by the American College of Cardiology
Although stents reduce the incidence of angiographic and
clinical restenosis of percutaneous coronary interventions,
they do not abolish restenosis altogether. Recently, it has
become apparent that restenosis after stenting may at times
be refractory to repeat balloon angioplasty (1,2). It has been
observed that when intra-stent restenosis presents focally,
balloon angioplasty is usually successful; however, when a
diffuse restenosis occurs, recurrent restenosis is likely (1,3).
This study investigated the causes of diffuse and other
patterns of restenosis after stenting.
METHODS
All lesions undergoing stent implantation at Centro Cuore
Columbus in Milan, Italy, are entered into a dedicated
database (Filemaker Pro, Claris) that includes baseline
clinical features, lesion characteristics, procedural variables
and outcomes. All patients with successful procedures are
asked to return in four to six months for a follow-up
angiogram, at which time they are evaluated for clinical
events and symptoms. Quantitative coronary angiography
was performed on baseline and follow-up angiograms. The
definitions related to restenosis are shown in Table 1.
Angiographic restenosis was defined as $50% diameter
stenosis on the follow-up angiogram. A diffuse restenosis
was defined as a follow-up lesion length $10 mm or a total
occlusion. A proliferative restenosis was defined as an
increase in lesion length from the time of the original
intervention to the follow-up angiogram. An aggressive
restenosis was defined as either a proliferative restenosis or
a restenotic narrowing that was tighter than the original
narrowing. A previous report from this institution identified
the characteristics predictive of angiographic restenosis (4).
For this analysis, characteristics were evaluated for predic-
tors of diffuse restenosis and aggressive restenosis. The
evaluated characteristics are listed in Table 2 and can be
organized as baseline clinical and angiographic features as
well as procedural characteristics.
Quantitative coronary angiography. Quantitative coro-
nary angiography was performed using computerized soft-
ware (Cardiovascular Measurement System, CMS, ME-
DIS, The Netherlands) with a contrast-filled catheter of
known diameter as a scaling device. The mean reference
artery diameter was interpolated from the proximal and
distal reference segments. The lesion length was measured
from “shoulder to shoulder.” When multiple narrowings
were present in a single artery, the lesions were considered
to be separate when occurring in different segments of the
artery (proximal, mid or distal) with at least 10 mm of
normal artery interposed between them. Otherwise the
lengths of the segments were added together and the lesion
was considered single. When a dissection occurred, or a new
narrowing appeared to develop after the initial balloon
inflation, only the original lesion length was used. The
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minimum lumen diameters (MLDs) before intervention,
after final balloon expansion of the stent and at follow-up
were measured. Acute gain, late loss and net gain were
calculated (5). When a lesion was totally occluded, the
lesion length was measured after opening the occlusion.
When this was not possible, a length was ascribed to the
narrowing that reflected the mean measured length of
totally occluded stenoses for the population overall
(20 mm).
Stent length was calculated as the sum of the nominal
lengths of each implanted stent. Stents were characterized
as being: 1) tubular (Palmaz-Schatz, Cordis/Johnson &
Johnson Interventional, Warren, New Jersey; AVE GFX,
Arterial Vascular Engineering, Inc., Santa Rosa, California;
Multilink, Guidant/Advanced Cardiovascular Systems,
Santa Clara, California; NIR, Medinol Ltd., Tel Aviv,
Israel; BeStent, Medtronic Interventional, San Diego, Cal-
ifornia; Pura and Pura-Vario, Devon Medical, Hamburg,
Germany); 2) coil (Gianturco-Roubin Flexstent, Cook In-
terventional, Bloomington, Indiana; Gianturco-Roubin 2,
Cook Interventional; Wiktor, Medtronic Interventional
Inc., San Diego, California; Cordis stent, Cordis/Johnson
& Johnson, Warren, New Jersey); or 3) mesh (Wallstent or
Magic Wallstent, Schneider Europe, Lausanne, Switzerland).
Statistical analysis. Categorical variables were assessed by
chi-square analysis. Normally distributed continuous vari-
ables are reported as mean 6 standard deviation and
compared by analysis of variance followed by the Scheffe F
test. Variables without normal distributions are presented as
median values and were evaluated with the Mann-Whitney
U or the Mantel-Cox log-rank test. A p value ,0.05 was
considered statistically significant.
The association between the restenosis outcomes (diffuse
restenosis or aggressive restenosis) and the potential predic-
tors was assessed via logistic regression methods. To allow
for correlation of type of restenosis within the same patient,
the random effect of patient on lesions was controlled for in
the logistic models using the generalized estimating equa-
tion methods of Zeger and Liang (6).
Factors that were biologically relevant and statistically
significant in a univariate analysis were included in the
multivariate analysis. Backward elimination was used to
eliminate potential predictors. The univariate and multivar-
iate odds ratios (ORs) and their corresponding 95% confi-
dence intervals (CIs) are given. The unit measurements used
to calculate the ORs were 1 mm for MLD and reference
lumen diameter, 10 mm for lesion length and stent length,
1 mm2 for intra-stent cross-sectional area and 10 years for
age. Outcomes specific to lesions, such as the length of
restenosis, were evaluated on a per-lesion basis. Outcomes
relating to patients, such as death or myocardial infarction
(MI), were evaluated on a per-patient basis.
RESULTS
From 1992 to 1997, 1,816 or 70% of stented lesions were
evaluated with follow-up angiography. Of these, 456 had a
follow-up stenosis diameter $50%, providing an overall
angiographic restenosis rate of 25%. A previous report from
this laboratory revealed the following characteristics as
predictive of intra-stent restenosis: 1) a smaller final intra-
stent cross-sectional area; 2) a longer total stent length; 3) a
smaller reference artery lumen diameter; 4) the presence of
a dissection; 5) older age and 6) prior history of coronary
artery bypass graft surgery (4).
Diffuse in-stent restenosis. Diffuse restenosis was seen in
286 of the 456 restenotic narrowings (63%), with 84 of these
presenting at follow-up as total occlusions (18% of all
in-stent restenotic narrowings or 4.6% of all stented le-
sions). Univariate and multivariate predictors of diffuse
restenosis are presented in Tables 2 and 3 respectively.
Diffuse restenosis was associated with a smaller reference
artery diameter, smaller baseline MLD, longer lesion
length, female gender and a smaller final minimal lumen
diameter. The stent type used, in particular coil design or
Wallstent, was also associated with diffuse restenosis. By
multivariate logistic regression, a longer baseline lesion
length, a smaller final result achieved and the use of coil
stents remained independent predictors of diffuse in-stent
restenosis.
When restenosis occurred inside Wiktor stents it was
diffuse 53% of the time, similar to the 58% incidence of
noncoil stents. Gianturco-Roubin II stents, however, were
associated with diffuse restenosis 91% of the time (p 5
0.003 compared with Wiktor stents).
Technical features associated with achieving larger intra-
stent luminal results were not associated with diffuse resten-
osis. Final balloon size used to expand the stent, balloon-
to-artery ratio or inflation pressures used were not
significantly different between diffuse and focal in-stent
restenosis. Diffuse restenosis was associated with smaller
final luminal dimensions compared with focally restenotic
lesions. There were 358 patients with more than one lesion
treated. Similar to other centers’ findings (7), we found that
when restenosis occurred in one of a patient’s lesions, other
lesions within that individual were more likely to have
restenosis (54% vs. 18%) when the first lesion did not
Abbreviations and Acronyms
CI 5 confidence interval
MI 5 myocardial infarction
MLD 5 minimum lumen diameter
OR 5 odds ratio
Table 1. Types of Restenosis
Restenosis $50% narrowing on follow-up angiogram
Focal restenosis Restenosis #10 mm in length
Diffuse restenosis Restenosis .10 mm in length
Proliferative restenosis Restenosis length longer than original length
Aggressive restenosis Restenosis that is longer and/or tighter than
the original lesion
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demonstrate restenosis (p , 0.001, OR 5.3). In the 118
instances when two or more lesions were restenotic in the
same patient, there was a strong correlation with the type
of restenosis (diffuse or focal) between the two lesions,
with an OR of 3.50 (CI 1.45 to 8.45, p 5 0.005) that if
one lesion was diffuse the other was more likely to be
diffuse.
Predictors of aggressive restenosis. An aggressive resten-
osis process was defined as either: 1) an increase in lesion
length; or 2) a decrease in MLD at the time of in-stent
restenosis compared with baseline. Lesions with aggressive
restenosis had greater late loss (2.2 6 0.7 vs. 1.9 6 0.6, p ,
0.0001), despite lesser acute gains during the intervention
(2.1 6 0.7 vs. 2.4 6 0.6, p , 0.0001). Predictors of an
aggressive restenosis process are shown in Tables 2 and 4.
Aggressive in-stent restenosis was more common in
women, in shorter lesions and with larger baseline
MLDs. The use of Wallstents, and long stent to lesion
length ratios, were associated with aggressive restenosis
as were less optimal results identified by intravascular
ultrasound. By multivariate logistic regression analysis
controlling for person effect, we found that female
gender, a large baseline MLD, a shorter baseline lesion
length and a greater stent to lesion length ratio were
predictors of aggressive restenosis.
Increase in lesion length or decrease in lumen diameter.
There was a correlation between the components of aggressive
restenosis, with proliferative lesions generally tighter than
nonproliferative lesions (57% vs. 34%, p , 0.0001). Aggressive
restenosis occurred earlier, and was earlier still when the lesion
was tighter and longer (Fig. 1). Patients with aggressive
restenosis were more likely to be symptomatic than those
without an aggressive restenosis (47% vs. 35%, p 5 0.05).
Myocardial infarctions before follow-up angiography were
more common with aggressive restenosis (6% vs. 2%, p 5 0.03)
and were particularly prevalent when the restenotic narrowing
was both tighter and longer (Fig. 2).
DISCUSSION
A report from this laboratory identified several characteris-
tics that predicted intra-stent restenosis (4). However, not
only the presence but also the severity of in-stent restenosis
carries clinical significance. For example, the length of the
Table 2. Characteristics Evaluated as Predictors of Diffuse or Aggressive In-Stent Restenosis (n 5 456)
Diffuse Focal p Aggressive Nonaggressive p
Clinical
Age (yrs) 59 6 10 60 6 11 0.3 60 6 10 59 6 11 0.2
Gender (% female) 13% 6% 0.01 12% 5% 0.03
Hypertension 44% 48% 0.3 46% 47% 0.8
Diabetes mellitus 9% 10% 0.9 9% 11% 0.6
History of smoking 61% 62% 0.9 60% 65% 0.5
Ejection fraction 59 6 11 58 6 11 0.6 58 6 11 58 6 12 0.6
Multivessel disease 68% 72% 0.3 69% 72% 0.5
Unstable angina 28% 32% 0.4 31% 28% 0.4
Restenotic lesion 17% 19% 0.6 17% 21% 0.4
Angiographic
Baseline MLD (mm) 0.7 6 0.5 0.8 6 0.5 0.02 0.8 6 0.5 0.6 6 0.4 ,0.001
Lesion length (mm) 16 6 9 12 6 7 ,0.0001 14 6 8 18 6 12 ,0.001
Reference diameter (mm) 2.9 6 0.5 3.0 6 0.6 0.007 2.9 6 0.5 3.0 6 0.5 0.1
Vessel treated (% LAD) 40% 36% 0.3 37% 39% 0.8
Ostial location 9% 15% 0.06 12% 8% 0.1
Baseline total occlusion 21% 12% 0.02 15% 24% 0.04
Bifurcation lesion 33% 30% 0.5 33% 26% 0.5
Fluoroscopic calcium 15% 17% 0.5 16% 13% 0.5
Fluoroscopic thrombus 2% 1.4% 0.7 2% 1% 0.5
Final MLD (mm) 2.9 6 0.6 3.1 6 0.6 0.0008 2.9 6 0.6 3.0 6 0.5 0.09
Procedural
Number of stents 2.2 6 1.5 1.9 6 1.4 0.2 2.1 6 1.3 2.1 6 1.6 0.9
Type of stent
Coil 27% 11% 0.0001 23% 18% 0.08
Wallstent 8% 4% 0.05 9% 2% 0.01
Length of stent (mm) 38 6 26 29 6 20 ,0.0001 36 6 25 33 6 22 0.3
Final balloon size (mm) 3.5 6 0.5 3.5 6 0.4 0.5 3.5 6 0.5 3.5 6 0.4 0.5
Balloon/artery ratio 1.23 6 0.19 1.20 6 0.20 0.1 1.23 6 0.20 1.20 6 0.19 0.3
Final pressure (atm) 16 6 4 16 6 4 0.9 15 6 4 16 6 4 0.2
Extra stents—dissection 19% 13% 0.1 18% 16% 0.7
Extra stents—additional Lesion not originally seen 17% 14% 0.4 17% 11% 0.1
Intravascular ultrasound (n 5 245)
Final intra-stent CSA (mm2) 6.4 6 2.0 7.0 6 1.9 0.02 6.5 6 2.0 7.0 6 1.8 0.04
CSA 5 cross-sectional area; LAD 5 left anterior descending; MLD 5 minimal lumen diameter.
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in-stent restenosis lesion has been identified as a marker for
the development of recurrent restenosis after repeat percu-
taneous intervention (1,2,8,9). A long in-stent restenotic
lesion is most likely to occur when the baseline lesion length
is long. However, a severe restenosis may occur even in short
original lesions, so alternative types of severe restenosis less
influenced by long baseline lesion lengths were also evalu-
ated in this study. This study evaluated the baseline and
procedural characteristics predictive of more clinically severe
restenoses. In this study an aggressive restenosis was in-
creasingly likely to present earlier and as a MI, compared
with nonaggressive restenotic lesions, supporting a clinical
relevance to this definition.
Diffuse and aggressive restenosis predictors. In addition
to the baseline lesion length, the presentation of a diffuse
restenosis was predicted by a smaller final luminal result
achieved inside the stent and by the use of specific coil
stents.
An aggressive restenosis, defined as the development of a
longer or tighter lesion at follow-up compared with base-
line, was predicted using multivariate logistic regression
analysis by the ratio of the stent length to the baseline lesion
length. The strong relationships between a large MLD at
baseline, or a short baseline lesion length, and the develop-
ment of an aggressive restenosis are artifacts of the defini-
tion of aggressive restenosis. A very small lumen diameter to
start with (such as a baseline total occlusion) has very little
room to become tighter, whereas a large baseline lumen is
more likely to be at least slightly smaller when restenosis
occurs. Similarly, a short lesion length was more likely to be
longer on follow-up. Women were more likely to develop an
aggressive restenosis, suggesting important person-related
effects.
Controllable characteristics. Some have proposed that
aggressive stent implantation techniques using oversized
balloons and/or high-pressure inflations may contribute to a
more aggressive restenotic process (10–12). In this study
there was little evidence that inflation pressures or balloon
sizes used to expand the stents were related to worsened
restenosis. Instead, the final result obtained, particularly as
Table 3. Predictors of Diffuse ($10 mm) In-Stent Restenosis (n 5 456) Controlling for Person Effects
Variables
Univariate Analysis Multivariate Analysis (r2 5 0.13)
Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
Clinical
Female gender 2.41 1.19–4.90 0.015 1.87 0.87–4.00 0.1
Alternate lesion diffuse 2.85 1.19–6.85 0.019 3.50 1.45–8.45 0.005
Angiographic
Baseline MLD 0.61/1 mm 0.40–0.91 0.02 0.83/1 mm 0.47–1.48 0.5
Reference artery diameter 0.59/1 mm 0.40–0.87 0.008 0.78/1 mm 0.45–1.34 0.4
Baseline total occlusion 1.65 0.95–2.88 0.08
Lesion length 2.16/10 mm 1.52–2.98 ,0.0001 1.70/10 mm 1.27–2.27 0.0004
Final MLD 0.46/1 mm 0.32–0.65 0.0005 0.57/1 mm 0.35–0.90 0.02
Procedural
Stent length 1.09/10 mm 0.95–1.26 0.20
Coil stents 1.62 1.01–2.59 0.04 2.29 1.11–4.69 0.02
Wallstents 2.73 0.99–7.54 0.05 2.70 0.90–8.13 0.08
Intravascular ultrasound
Final CSA (245 lesions) 0.85/1 mm2 0.73–0.99 0.04 0.93 0.78–1.12 0.5
CI 5 confidence interval; CSA 5 cross-sectional area; MLD 5 minimum lumen diameter.
Table 4. Predictors of an Aggressive Restenosis—The Development of a Longer or Tighter Lesion at Follow-Up Compared With
Baseline (n 5 456) Controlling for Person Effects
Variables
Univariate Analysis Multivariate Analysis (r2 5 0.12)
Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
Clinical
Female gender 3.73 1.43–9.73 0.007 2.76 1.03–7.39 0.04
Alternate lesion aggressive 0.90 0.58–1.40 0.6
Angiographic
MLD at baseline 2.74/1 mm 1.81–4.15 ,0.0001 5.13/1 mm 2.57–10.2 0.0007
Baseline total occlusion 0.56 0.50–1.14 0.2
Lesion length 0.52/10 mm 0.44–0.63 ,0.0001 0.68/10 mm 0.50–0.91 0.01
Procedural
Stent length/lesion length 1.32 1.01–1.15 0.03 1.31 1.03–1.67 0.03
Wallstents 8.81 1.18–66.00 0.03 1.65 0.64–4.24 0.3
Intravascular ultrasound
Final CSA 0.87/1 mm2 0.76–1.00 0.05 0.90/1 mm2 0.78–1.03 0.1
CI 5 confidence interval; CSA 5 cross-sectional area; MLD 5 minimum lumen diameter.
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identified by intravascular ultrasound, was consistently re-
lated to the restenotic process, with larger final results associ-
ated with more favorable angiographic outcomes (Fig. 3) (4).
An unusual relationship between acute gain and late loss
is present for lesions developing an aggressive restenosis.
Typically there is a direct relationship between acute gain
and late loss, as a larger tax is imposed with greater degrees
of lesion expansion (5). However, aggressive restenotic
lesions demonstrated an inverse relationship, with less acute
gain but greater late loss. This conflicts with the theory that
aggressive stent expansion leads to aggressive restenosis.
Stent selection. The prevalent finding that coil stents and
Wallstents had higher associations with the presence and
severity of restenosis suggests there may be important
relationships between certain stent types and the restenotic
process. In randomized studies, a higher angiographic
restenosis rate was seen with the Gianturco-Roubin II stent
compared with the Palmaz-Schatz stent (13). In this study
Gianturco-Roubin II coil stents were strongly associated
with diffuse restenosis. These studies together suggest there
is an important interaction of stent design with the rest-
enotic process.
Previous analysis has supported a relationship between
the amount of metal implanted and the development of
in-stent restenosis (4). The current analysis demonstrates a
strong association with the amount of metal implanted and
the development of a proliferative restenosis. A significant
predictor of an increase in lesion length was the stent to
lesion length ratio. This ratio was not predictive of any
angiographic restenosis, however. It appears that the inter-
action of the metal with the arterial wall promotes intimal
proliferation in a subset of individuals. When this predilec-
tion is not present, additional stent length may help in
achieving an optimal luminal result along the length of the
Figure 1. Relationship of type of restenosis with time to follow-up, presented as mean 6 standard error of the mean. The more aggressive the restenotic
process, the earlier the patient presented with restenosis. When both components of aggressive restenosis were present, the follow-up was earlier than when
only one component was present. *p , 0.05 compared with the nonaggressive group.
Figure 2. Relationship between the type of restenosis and the development of a myocardial infarction within six months. The incidence of myocardial
infarction increases as the degree of severity of the restenosis increases. p , 0.05 comparing the nonaggressive group with each of the others.
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artery. However, when this predilection is present, the
resultant restenosis tends to extend further along the length
of the stented segment.
Restenosis as a nondichotomous variable. The current
study showed that the most important characteristics pre-
dicting the presence or absence of restenosis were also
important in predicting the severity of restenosis (Fig. 3).
This suggests that restenosis is a graded, not merely a
dichotomous, process. Large arteries are more commonly
free of restenosis after stenting, whereas small arteries
develop not only restenosis but diffuse and/or aggressive
restenosis, with intermediate arteries presenting with less
severe forms.
The tradition of considering the restenotic process as
strictly dichotomous may have directed attention away from
clinically relevant differences. For example, two different
stent types may have similar rates of restenosis, but if one
presents in a simple, easily treated fashion and the other
presents in a complex, more refractory manner, clinical
differences may be significant. None of the randomized
trials of stenting to date have reported on the characteristics
of restenosis.
Study limitations. This analysis is retrospective and un-
controlled. There were wide variations in lesion character-
istics, stent types and strategies employed. Multiple statis-
tical analyses were performed, making it possible that some
of the associations were due to type I errors. Consistency of
relationships across different analyses should be considered
more important than any single finding alone.
The end points of this analysis depended upon the
quantitative coronary angiographic determinations of the
measured lesion length; however, this measurement carries
greater subjectivity than other quantitative angiographic
determinants. In-stent restenosis often presents as closely
grouped sequential narrowings as opposed to single, specific
lesions. Precise definitions of single versus multiple lesions
within an artery were prospectively created and adhered to
when the quantitative angiographic measurements were
performed to minimize subjectivity.
Follow-up after in-stent restenosis was not available for
this study. However, more MIs and earlier presentations
occurred as the restenosis severity increased, supporting an
important clinical significance of the degree of restenosis
severity. Other investigators have found correlations with
the severity of restenosis presented and an increased likeli-
hood of further events (14,15).
Conclusions. Markers for diffuse restenosis were also im-
portant markers for the presence of any restenosis and
included the baseline lesion length, the length of stent
implanted, the final result achieved inside the stented
segment and the stent type used. An important marker for
a proliferative restenosis was the relative length of stent
implanted to the original lesion length. When aggressive
forms of in-stent restenosis occur, they tend to present
earlier and are more likely to present as a MI. More careful
consideration of the type of in-stent restenosis may aid in
identifying when alternative strategies may be useful.
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